Does the Washington Post Have a Conflict of Interest in its Editorials?

If you are one of those people who believes there is no such thing as a coincidence, you'll have to ask if the Washington Post is pushing one of its editors' spousal agendas.

Reuters reported a while back that the Federal Trade Commission was considering ending "pay for delay" practices with generic drugs.

Basically, when a generic drug manufacturer is ready to come on the scene with a generic, a name brand pharmaceutical company pays the generic to delay entry to the market. Well, the FTC...